How long does Enasidenib last?

Enasidenib is an oral targeted therapy mainly used to treat acute myeloid leukemia (AML), especially those with IDH2 mutations. The recommended dose of this drug is 100 mg taken orally once daily with or without food until disease progression or unacceptable toxicity occurs. The duration of treatment usually depends on the patient's disease response and drug tolerance.

Generally speaking, the effect of ensidipine usually lasts for more than 6 months when the patient does not have disease progression or unacceptable side effects. After 6 months of treatment, patients will have enough time to observe clinical response and decide whether to continue using the drug. During the patient's treatment with ensidipine, the doctor will regularly evaluate the development of the patient's condition and adjust the treatment plan based on the treatment response. If the patient does not experience disease progression and significant toxicity within 6 months, treatment may continue.

However, the potency of ensidipine is not infinite. Although it has a good therapeutic effect on AML patients with IDH2 mutations, as the treatment time is prolonged, some patients may develop drug resistance or have adverse drug reactions, which may affect the sustainability of the drug effect. Therefore, the doctor will decide whether to adjust the medication or switch to other treatment options based on the patient's specific situation.

The therapeutic goal of ensidipine is to restore the normal differentiation of leukemia cells and effectively reduce the proliferation of leukemia cells by targeting the enzyme activity of IDH2 mutations. In clinical practice, drug efficacy is usually manifested as hematological improvement, including recovery of white blood cell count and increase in hemoglobin levels. However, as the disease progresses, patients may experience recurrence of the disease, at which time further treatment may be required.

Reference materials:https://www.idhifa.com/